Healthcare | April 14, 2023
Max Healthcare Institute completes acquisition of further stake in Eqova Healthcare
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Subscribe To Our Newsletter & Stay Updated
